Global healthcare company Abbott (NYSE:ABT) announced on Monday the release of Libre Assist, a new feature within the Libre app.
Libre Assist is designed to help people living with diabetes in the US better understand how the foods they eat affect their glucose levels. Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist is designed to help people make informed mealtime decisions before they eat.
Using generative artificial intelligence (AI), the feature illustrates the potential glucose impact of a food choice with a color-coded rating system -- green for minor, yellow for moderate, and orange for major.
Abbott is launching the new technology during CES 2026 in Las Vegas.
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes